NAM
LAB icon

Nexpoint Asset Management’s Standard BioTools LAB Stock Holding History

Nexpoint Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,447
Closed -$34.1K – 94
2023
Q4 		$34.1K Buy
+15,447
New +$33K 0.01% 66

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Nexpoint Asset Management's LAB Position: Q1 2024 in Review

Nexpoint Asset Management sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 15,447 shares — an estimated $34.1K sold.

Nexpoint Asset Management first reported a position in LAB in Q4 2023 and held it in 1 quarter. The position peaked at $34.1K in Q4 2023. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2024.

  • Nexpoint Asset Management reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
  • Nexpoint Asset Management sold 15,447 Standard BioTools shares in Q1 2024, an estimated $34.1K.
  • Nexpoint Asset Management first reported a position in Standard BioTools in Q4 2023 and held it in 1 quarter.
  • Nexpoint Asset Management's Standard BioTools position peaked at $34.1K in Q4 2023.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.

Based on Nexpoint Asset Management's 13F filing for Q1 2024, filed 15 May 2024.